Peripheral Artery Disease - US Drug Forecast and Market Analysis to 2024
|出版日期||內容資訊||英文 260 Pages
|週邊動脈疾病 (PAD):美國的醫藥品市場預測與分析 Peripheral Artery Disease - US Drug Forecast and Market Analysis to 2024|
|出版日期: 2015年10月01日||內容資訊: 英文 260 Pages||
本報告提供美國的週邊動脈疾病 (以下PAD)的治療藥臨床實驗趨勢與上市預測相關分析，PAD概要 (病因、病理、症狀、診斷方法等在) ，及目前的主要的治療方法，現在臨床實驗中/已上市的開發中產品的概要 (功效，SWOT分析等)，市場規模預測 (總計11年份)，主要的推動市場要素與其影響度等相關的調查評估。
In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which GlobalData believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co.'s Zontivity (vorapaxar), AstraZeneca's Brilinta (ticagrelor), and Bayer and Janssen's (a subsidiary of Johnson & Johnson) Xarelto (rivaroxaban), which have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape.
The total US sales for the PAD therapeutics market in the 2014 base year was approximately $191.4m. The statin share can chiefly be attributed to sales volume, as most statins, with the exception of Crestor, are available as inexpensive generics.